Package Leaflet: Information for the User
INTELENCE 200 mg tablets
etavirine
Read this leaflet carefully before you start taking this medicine, because
it contains important information for you.
INTELENCE contains the active ingredient etravirina. INTELENCE belongs to a group of medications against HIV called non-nucleoside reverse transcriptase inhibitors (NNRTIs).
INTELENCE is a medication used in the treatment of Human Immunodeficiency Virus (HIV) infection. INTELENCE acts by reducing the amount of HIV in the body. This way, your immune system will improve and the risk of developing diseases related to HIV infection will decrease.
INTELENCE is used in combination with other HIV medications to treat adults and children 6 years of age and older who are infected with HIV and have already used other HIV medications.
Your doctor will explain the most suitable combination of medications for you.
Do not take INTELENCE
Warnings and precautions
Consult your doctor or pharmacist before starting to take INTELENCE.
INTELENCE does not cure HIV infection. It is part of a treatment that reduces the amount of virus in the blood. While taking this medication, you may still be able to transmit HIV to others, although effective antiviral treatment reduces the risk. Consult your doctor about the precautions you need to take to avoid infecting others.
Older patients
INTELENCE has only been used in a limited number of patients aged 65 years or older.
Discuss the use of INTELENCE with your doctor if you belong to this age group.
Weight and increase in lipid and glucose levels in the blood
During HIV treatment, there may be an increase in weight and levels of glucose and lipids in the blood. This may be partly related to recovery of health and lifestyle, and in the case of lipids in the blood, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Bone problems
Some patients taking combined antiretroviral therapy may develop a bone disease called osteonecrosis (bone tissue death caused by loss of blood supply to the bone). The duration of combined antiretroviral therapy, use of corticosteroids, alcohol consumption, severe immunosuppression, increased body mass index, among others, may be one of the many risk factors for developing this disease. Signs of osteonecrosis include joint stiffness, pain, and discomfort (especially in the hip, knee, and shoulder) and difficulty moving. If you notice any of these symptoms, please consult your doctor.
Inform your doctor about your situation
Check the following points and inform your doctor if you are in any of these situations.
Children and adolescents
Do not give this medication to children under 6 years of age and weighing less than 16 kg, as the potential benefit or risk has not yet been established.
INTELENCE with other medications
INTELENCE may interact with other medications. Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Most of the time, INTELENCE can be combined with HIV medications from another group. However, there are some combinations that are not recommended. In other cases, it may be necessary to increase monitoring and/or modify the medication dose. That's why you should always inform your doctor if you are taking other HIV medications. Also, be sure to read the leaflets that accompany these medications carefully. Follow your doctor's instructions carefully about the medications that can be combined.
Do not recommend combining INTELENCE with any of the following medications:
If you are taking any of the products listed, consult your doctor.
The effects of INTELENCE or other medications may be affectedif you take
INTELENCE with any of the following medications. You may need to change the dose of some medications, as their therapeutic effect or adverse effects may be affected when combined with INTELENCE. Inform your doctor if you are taking:
Pregnancy and breastfeeding
If you are pregnant, inform your doctor immediately. Pregnant women should not take INTELENCE, unless your doctor specifically advises you to do so.
Infected mothers should not breastfeed their children, as there is a possibility that the child may contract HIV infection.
Driving and operating machinery
Do not operate machinery or drive if you experience drowsiness or dizziness after taking your medication.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Use in adults
The recommended dose of INTELENCE is one tablet twice a day.
Take one tablet of 200 mg of INTELENCE in the morning after a meal.
Take one tablet of 200 mg of INTELENCE in the evening after a meal.
Use in children and adolescents from 6 years of age and with a weight of at least 16 kg
Your doctor will indicate the correct dose based on the child's weight.
Your doctor will inform you exactly how much INTELENCE the child should take.
Instructions for taking INTELENCE for all patients
It is essential to take INTELENCE after meals. If you take INTELENCE on an empty stomach, only half of the INTELENCE amount is absorbed. Follow your doctor's instructions on the type of food you should take with INTELENCE.
Swallow the INTELENCE tablets whole with a glass of water. Do not chew the tablets.
Child-resistant cap removal
The plastic bottle has a child-resistant cap that opens as follows: Push the plastic cap down while turning it counterclockwise.
|
If you take more INTELENCE than you should
Inform your doctor or pharmacist immediately. The most common adverse effects of INTELENCE are skin rash, diarrhea, nausea, and headache (see section “4. Possible adverse effects”).
If you forgot to take INTELENCE
If you realizewithin 6 hours of the usual INTELENCE taking time,take the tablet as soon as possible. Take the tablet always after a meal.
Then take the next dose as usual. If you realizeafter 6 hours,omit that dose and take the next one at the usual time. Do not take a double dose to compensate for the missed doses.
If you vomit within less than 4 hours after taking INTELENCE, take another tablet after a meal. If you vomit more than 4 hours after taking INTELENCE, it is not necessary to take another tablet until the next scheduled dose.
Consult your doctor if you have doubts about what to do if you miss a dose or vomit.
Do not stop taking INTELENCE without first talking to your doctor
The HIV treatment may increase your sense of well-being. Although you feel better, do not stop taking INTELENCE or the other HIV medications. If you do, you may increase the risk of the virus becoming resistant. Consult your doctor first.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
The frequency of side effects associated with INTELENCE is shown below.
Very common side effects (may affect more than 1 in 10 people)
Your doctor will instruct you on how to act on your symptoms and whether you should stop taking INTELENCE;
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Side effects of unknown frequency (frequency cannot be estimated from available data)
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this prospectus. You can also report them directly through the national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the carton box and on the bottle after CAD. The expiration date is the last day of the month indicated.
Do not use after 6 weeks from the first opening of the bottle.
INTELENCE tablets must be stored in the original bottle and keep the bottle perfectly closed to protect it from moisture. The bottle contains 3 sachets (desiccants) to keep the tablets dry. These sachets must be kept in the bottle at all times and must not be ingested.
Medicines should not be thrown down the drains or in the trash. Ask your pharmacist how to dispose of the containers and the medications that you no longer need. In this way, you will help protect the environment.
Composition of INTELENCE
Appearance of the product and contents of the pack
This medicinal product is presented in the form of a white to off-white, biconvex, oblong tablet with the indication “T200” engraved on one side.
Plastic bottle with 60 tablets and 3 sachets to keep the tablets dry.
Marketing Authorisation Holder
Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
Responsible for manufacturing
Janssen-Cilag SpA, Via C. Janssen, 04100 Borgo San Michele, Latina, Italy
For more information about this medicinal product, please contact the local representative of the marketing authorisation holder:
België/Belgique/Belgien Janssen-Cilag NV Antwerpseweg 15-17 B-2340 Beerse Tel/Tél: +32 14 64 94 11 | Lietuva UAB "JOHNSON & JOHNSON" Konstitucijos pr. 21C LT-08130 Vilnius Tel: +370 5 278 68 88 |
„??????? & ??????? ????????” ???? ?.?. ??????? 4 ?????? ???? ?????, ?????? 4 ????? 1766 ???.: +359 2 489 94 00 | Luxembourg/Luxemburg Janssen-Cilag NV Antwerpseweg 15-17 B-2340 Beerse Belgique/Belgien Tél/Tel: +32 14 64 94 11 |
Czech Republic Janssen-Cilag s.r.o. Walterovo námestí 329/1 CZ158 00 Praha 5 – Jinonice Tel: +420 227 012 227 | Magyarország Janssen-Cilag Kft. Nagyenyed u. 8-14 H-Budapest, 1123 Tel.: +36 1 884 2858 |
Denmark Janssen-Cilag A/S Bregnerødvej 133 DK-3460 Birkerød Tlf: +45 45 94 82 82 | Malta AM MANGION LTD. Mangion Building, Triq Gdida fi Triq Valletta MT-Hal-Luqa LQA 6000 Tel: +356 2397 6000 |
Germany Janssen-Cilag GmbH Johnson & Johnson Platz 1 D-41470 Neuss Tel: +49 2137 955-955 | Netherlands Janssen-Cilag B.V. Graaf Engelbertlaan 75 NL-4837 DS Breda Tel: +31 76 711 1111 |
Estonia UAB "JOHNSON & JOHNSON" Eesti filiaal Lõõtsa 2 EE-11415 Tallinn Tel: +372 617 7410 | Norway Janssen-Cilag AS Postboks 144 NO-1325-Lysaker Tlf: +47 24 12 65 00 |
Greece Janssen-Cilag Farmakéutik? Α.Ε.Β.Ε. Λeωf?ρος Ειρ?νης 56 GR-151 21 Πe?κη, Αθ?νa Tηλ: +30 210 80 90 000 | Austria Janssen-Cilag Pharma GmbH Vorgartenstraße 206B A-1020 Wien Tel: +43 1 610 300 |
Spain Janssen-Cilag, S.A. Paseo de las Doce Estrellas,5-7 E-28042 Madrid Tel: +34 91 722 81 00 | Poland Janssen-Cilag Polska Sp. z o.o. ul. Ilzecka 24 PL-02-135 Warszawa Tel.: +48 22 237 60 00 |
France Janssen-Cilag 1, rue Camille Desmoulins, TSA 91003 F-92787 Issy Les Moulineaux, Cedex 9 Tél: 0 800 25 50 75 / +33 1 55 00 40 03 | Portugal Janssen-Cilag Farmacêutica, Lda. Lagoas Park, Edifício 9 2740-262 PORTO SALVO PORTUGAL Tel: +351 214 368 600 |
Croatia Johnson & Johnson S.E. d.o.o. Oreškoviceva 6h 10010 Zagreb Tel: +385 1 6610 700 | Romania Johnson & Johnson România SRL Str. Tipografilor nr. 11-15 Cladirea S-Park, Corp B3-B4, Etaj 3 013714 Bucuresti, ROMÂNIA Tel: +40 21 207 1800 |
Ireland Janssen-Cilag Ltd. 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG United Kingdom Tel: +44 1 494 567 444 | Slovenia Johnson & Johnson d.o.o. Šmartinska cesta 53 SI-1000 Ljubljana Tel: +386 1 401 18 00 |
Iceland Janssen-Cilag AB c/o Vistor hf. Hörgatúni 2 IS-210 Garðabær Sími: +354 535 7000 | Slovakia Johnson & Johnson s.r.o. CBC III, Karadžicova 12 SK-821 08 Bratislava Tel: +421 232 408 400 |
Italy Janssen-Cilag SpA Via M.Buonarroti, 23 I-20093 Cologno Monzese MI Tel: +39 02 2510 1 | Finland Janssen-Cilag Oy Vaisalantie/Vaisalavägen 2 FI-02130 Espoo/Esbo Puh/Tel: +358 207 531 300 |
Cyprus Βaρν?ßaς Χatζηpaνaγ?ς Λtd, Λeωf?ρος Gι?ννου Κρaνιdι?tη 226 Λatsι? CY-2234 Λeυκωs?a Τηλ: +357 22 207 700 | Sweden Janssen-Cilag AB Box 4042 SE-16904 Solna Tel: +46 8 626 50 00 |
Lithuania UAB "JOHNSON & JOHNSON" filiale Latvija Mukusalas iela 101 Riga, LV-1004 Tel: +371 678 93561 | United Kingdom Janssen-Cilag Ltd. 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG - UK Tel: +44 1 494 567 444 |
Last update of this leaflet:{MM/AAAA}
The detailed information on this medicinal product is available on the website of the European Medicines Agencyhttp://www.ema.europa.eu.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.